Date: 01/09/2017

Member: DERRICK COLLINS

D/O/B: 08/05/1975

CVS/caremark

To: Dr. DERRICK JONES 2925 SKYWAY CIR N IRVING, TX 75038-3510

(UR)

Fax number: 972-919-0425

Therapeutic alert

Diabetes and hypertension without ACEI or ARB

An analysis of prescription claims suggests that your patient with diabetes and hypertension is not on an Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin-II Receptor Blocker (ARB). Both medications have been shown to slow the progression of diabetic nephropathy.^{1,2}

Clinical consideration

Add an ACEI or ARB.*

Guideline summary

In patients with type 2 diabetes, hypertension, and normoalbuminuria, renin-angiotensin system inhibition has been demonstrated to delay onset of elevated albuminuria and reduce CVD outcomes.² Thiazide diuretics, beta blockers, and calcium channel blockers can be used as additional therapy to further lower blood pressure in patients or as alternative therapy when there is an intolerance to ACEI's or ARBs.² Note that combinations of two or more drugs are usually needed to achieve a target blood pressure goal. ACEIs or ARBs should be first line agents unless contraindicated.^{1,2}

¹James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guidelines for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014; 311(5): 507-520.

²American Diabetes Association. Standards of medical care in diabetes-2016. *Diabetes Care*. 2016; 39(suppl 1): S1-S118.

We defer to your judgment for this patient

We recognize that patient variables, unavailable to us, may make the current therapy appropriate for this individual. You are best qualified to balance quality and cost of care when treating your patients.

You don't have to confirm your action or reply to this fax - unless you wish

If you have comments, fax toll free to 1-866-799-6048. This fax machine is secured in accordance with applicable law.

28-DIA7NW

Reference: 803098772 - 7193073 - 25401



45204185

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, retention or copying of it or its contents is prohibited. If you have received this communication in error, please notify us immediately by telephone toll-free at 1-866-530-4089 or e-mail to mdmail@caremark.com and immediately and securely destroy all copies of this communication and any attachments. Whether or not you notify the sender of the error, you agree not to use or disclose the information for any purpose or to compromise its confidentiality. This communication has been sent from a secure location that meets the requirements of HIPAA and other applicable-regulations. Returned communication transmissions will be received with an equal level of compliance. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle our members' private health information.

^{*} Changes in therapy will require monitoring of blood pressure, renal function and serum potassium.

grander figgs , and the substitute the first of a confidence and the substitute of t